Diffuse large B-cell lymphoma: what clinical progress have we seen in the last 5 years?

In modern DLBCL therapy, it is critical to identify individuals at increased risk of primary treatment failure with R-CHOP, who may then be offered the addition of Polatuzumab Vedotin or other targeted therapies in frontline. CAR-T is now a treatment standard in second line for patients with primary refractory or early relapsed disease, with ASCT reserved for eligible patients with later relapse, who may subsequently receive CAR-T in third-line. ASCT ineligible patients also face improved outcomes with CAR-T and enhanced therapies incorporating novel agents. Molecular and genomic tumor profiling is likely in the future to direct optimal treatment for patients by identifying biologically distinct lymphomas sensitive to distinct targeted agents.